Immuneering, a Cambridge, MA-based new medicine developer, closed a $17m Series A financing.
The round was led by Boxcar PMJ LLC.
Concurrent with the financing, Boxcar’s founding partner Joseph Kekst will join Immuneering’s board of directors and Boxcar’s founding partner Peter Feinberg will join as an observer.
The company plans to use the proceeds to advance its lead program in cancer cachexia and its pipeline of oncology medicines driven by its Disease Cancelling Technology (DCT), develop its technology platforms, launch new drug programs in other disease areas and support the growth of its computational biology services business.
Led by Ben Zeskind, Ph.D., MBA, co-founder and CEO, Immuneering leverages bioinformatics to develop new medicines. Its current pipeline of drug candidates is focused on treating cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Concurrent with its internal programs, Immuneering provides computational biology services to pharmaceutical and biotechnology companies.